JP2020511991A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511991A5 JP2020511991A5 JP2019553350A JP2019553350A JP2020511991A5 JP 2020511991 A5 JP2020511991 A5 JP 2020511991A5 JP 2019553350 A JP2019553350 A JP 2019553350A JP 2019553350 A JP2019553350 A JP 2019553350A JP 2020511991 A5 JP2020511991 A5 JP 2020511991A5
- Authority
- JP
- Japan
- Prior art keywords
- lentiviral vector
- item
- vector according
- cell
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023005869A JP2023033551A (ja) | 2017-03-29 | 2023-01-18 | ヘモグロビン異常症を治療するためのベクターおよび組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478375P | 2017-03-29 | 2017-03-29 | |
| US62/478,375 | 2017-03-29 | ||
| US201762489149P | 2017-04-24 | 2017-04-24 | |
| US62/489,149 | 2017-04-24 | ||
| PCT/US2018/025165 WO2018183692A1 (en) | 2017-03-29 | 2018-03-29 | Vectors and compositions for treating hemoglobinopathies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023005869A Division JP2023033551A (ja) | 2017-03-29 | 2023-01-18 | ヘモグロビン異常症を治療するためのベクターおよび組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511991A JP2020511991A (ja) | 2020-04-23 |
| JP2020511991A5 true JP2020511991A5 (cg-RX-API-DMAC7.html) | 2021-04-30 |
| JP7228523B2 JP7228523B2 (ja) | 2023-02-24 |
Family
ID=63677097
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553350A Active JP7228523B2 (ja) | 2017-03-29 | 2018-03-29 | ヘモグロビン異常症を治療するためのベクターおよび組成物 |
| JP2023005869A Withdrawn JP2023033551A (ja) | 2017-03-29 | 2023-01-18 | ヘモグロビン異常症を治療するためのベクターおよび組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023005869A Withdrawn JP2023033551A (ja) | 2017-03-29 | 2023-01-18 | ヘモグロビン異常症を治療するためのベクターおよび組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12703864B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3600448A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7228523B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110582305A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018243293A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019020322A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3057862A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL269551A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201908844YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018183692A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61387B2 (sr) | 2013-02-15 | 2024-06-28 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| SG11201908844YA (en) * | 2017-03-29 | 2019-10-30 | Bluebird Bio Inc | Vectors and compositions for treating hemoglobinopathies |
| EP3942046A1 (en) * | 2019-03-22 | 2022-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Bifunctional vectors allowing bcl11a silencing and expression of an anti-sickling hbb and uses thereof for gene therapy of b- hemoglobinopathies |
| JP7853100B2 (ja) * | 2019-06-05 | 2026-04-28 | オーチャード セラピューティクス(ヨーロッパ)リミテッド | 真核細胞を修飾するための組成物及び方法 |
| JP7803014B2 (ja) * | 2019-09-30 | 2026-01-21 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| CN117384967A (zh) * | 2020-04-24 | 2024-01-12 | 康霖生物科技(杭州)有限公司 | 一种核酸构建体 |
| EP4222271A4 (en) * | 2020-11-23 | 2025-07-30 | Intas Pharmaceuticals Ltd | LENTIVIRUS VECTOR GENE THERAPY-BASED DELIVERY FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US5928638A (en) | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
| US8101349B2 (en) | 1997-12-23 | 2012-01-24 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells and their methods of use II |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| ES2348868T3 (es) | 2002-12-13 | 2010-12-16 | Genetix Pharmaceuticals Inc. | Vectores retrovirales terapeuticos para terapia genica. |
| CA2566286A1 (en) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| US20080051431A1 (en) | 2006-05-26 | 2008-02-28 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds in combination therapy |
| EP3031916B1 (en) | 2007-06-11 | 2017-06-07 | Takara Bio Inc. | Method for expression of specific gene |
| GB0713183D0 (en) | 2007-07-06 | 2007-08-15 | King S College London | Method |
| US20110294144A1 (en) | 2008-02-12 | 2011-12-01 | Kenichi Noguchi | Screening method |
| ES2738980T3 (es) | 2008-09-15 | 2020-01-28 | Childrens Medical Ct Corp | Modulación de BCL11A para el tratamiento de hemoglobinopatías |
| US20110294114A1 (en) | 2009-12-04 | 2011-12-01 | Cincinnati Children's Hospital Medical Center | Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells |
| WO2011072086A1 (en) | 2009-12-08 | 2011-06-16 | Hemaquest Pharmaceuticals, Inc. | Methods and low dose regimens for treating red blood cell disorders |
| WO2012073047A2 (en) | 2010-12-03 | 2012-06-07 | Genome Research Limited | Compositions and methods |
| WO2012079046A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
| DK2717922T3 (en) | 2011-06-10 | 2019-01-07 | Bluebird Bio Inc | GENERATIVE VECTORS FOR ADDRENOLEUCODYSTROPHY AND ADDRENOMYELONE EUROPE |
| CA2850484C (en) | 2011-09-30 | 2021-01-26 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| ES2708948T3 (es) | 2012-11-27 | 2019-04-12 | Childrens Medical Ct Corp | Elementos reguladores distales de bcl11a como dianas para la reinducción de la hemoglobina fetal |
| US10106816B2 (en) * | 2012-12-14 | 2018-10-23 | Case Western Reserve University | Genomic RNA packaging enhancer element |
| WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
| ES2721936T3 (es) | 2013-11-13 | 2019-08-06 | Childrens Medical Center | Regulación de la expresión genética mediada por las nucleasas |
| US10982339B2 (en) | 2014-04-25 | 2021-04-20 | C2Cnt Llc | Process for the production of ammonia from air and water |
| WO2015164739A1 (en) * | 2014-04-25 | 2015-10-29 | Bluebird Bio, Inc. | Kappa/lambda chimeric antigen receptors |
| CN106794260B (zh) | 2014-04-25 | 2021-02-23 | 儿童医疗中心有限公司 | 治疗血红蛋白病的组合物和方法 |
| WO2015164759A2 (en) | 2014-04-25 | 2015-10-29 | Bluebird Bio, Inc. | Mnd promoter chimeric antigen receptors |
| BR112017004349A2 (pt) | 2014-09-04 | 2017-12-05 | Memorial Sloan Kettering Cancer Center | terapia com gene de globina para o tratamento de hemoglobinopatias |
| US10383929B2 (en) * | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| KR102598130B1 (ko) | 2015-03-31 | 2023-11-02 | 글리코토페 게엠베하 | 글로빈 유전자 클러스터의 조절 요소를 포함하는 진핵생물 발현 벡터 |
| WO2016182893A1 (en) | 2015-05-08 | 2016-11-17 | Teh Broad Institute Inc. | Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof |
| EP4014996A1 (en) | 2015-08-31 | 2022-06-22 | Helixmith Co., Ltd | Anti-sialyl tn chimeric antigen receptors |
| GB201522243D0 (en) | 2015-12-16 | 2016-01-27 | Ucl Business Plc | Treatment |
| KR20250134722A (ko) | 2016-02-12 | 2025-09-11 | 블루버드 바이오, 인코포레이티드. | Vcn 인핸서 조성물 및 이의 사용 방법 |
| US11261441B2 (en) * | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
| SG11201908844YA (en) * | 2017-03-29 | 2019-10-30 | Bluebird Bio Inc | Vectors and compositions for treating hemoglobinopathies |
-
2018
- 2018-03-29 SG SG11201908844Y patent/SG11201908844YA/en unknown
- 2018-03-29 JP JP2019553350A patent/JP7228523B2/ja active Active
- 2018-03-29 CN CN201880027694.4A patent/CN110582305A/zh active Pending
- 2018-03-29 EP EP18775163.1A patent/EP3600448A4/en active Pending
- 2018-03-29 BR BR112019020322-2A patent/BR112019020322A2/pt not_active Application Discontinuation
- 2018-03-29 CA CA3057862A patent/CA3057862A1/en active Pending
- 2018-03-29 AU AU2018243293A patent/AU2018243293A1/en not_active Abandoned
- 2018-03-29 WO PCT/US2018/025165 patent/WO2018183692A1/en not_active Ceased
-
2019
- 2019-09-23 IL IL26955119A patent/IL269551A/en unknown
-
2022
- 2022-01-28 US US17/587,999 patent/US12703864B2/en active Active
-
2023
- 2023-01-18 JP JP2023005869A patent/JP2023033551A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504635A5 (cg-RX-API-DMAC7.html) | ||
| US12234476B2 (en) | VCN enhancer compositions and methods of using the same | |
| US20220259594A1 (en) | Vectors and compositions for treating hemoglobinopathies | |
| EP2169073B1 (en) | Vector for the preparation of immunotherapeutical compositions | |
| EP2760994B2 (en) | Compounds for improved viral transduction | |
| AU2015315726B2 (en) | Lentiviral vector for treating hemoglobin disorders | |
| JP2014530012A5 (cg-RX-API-DMAC7.html) | ||
| US11976293B2 (en) | Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies | |
| JP2015529466A (ja) | 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター | |
| US20220073951A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
| US11326183B2 (en) | VCN enhancer compositions and methods of using the same | |
| CN1522160A (zh) | 编码人珠蛋白基因的载体及其在治疗血红蛋白病中的应用 | |
| US11261441B2 (en) | Vectors and compositions for treating hemoglobinopathies | |
| US20250235480A1 (en) | Vectors combining anti-sickling beta-as3-globin with anti bcel11a shrnamir to treat beta-hemoglobinopathies | |
| WO2019213011A1 (en) | Compositions and methods for hemoglobin production | |
| EP3931338A1 (en) | Augmentations to lentiviral vectors (cclc-mgata/ank-core lcr-beta-as3-fb) to increase expression | |
| WO2023038055A1 (ja) | レトロウイルスベクター製造用の核酸 | |
| Malik et al. | Genetically engineered cures: gene therapy for sickle cell disease | |
| CN120187857A (zh) | 调控序列及其用途 | |
| HK1093523B (en) | Lentiviral vectors for the preparation of immunotherapeutical compositions |